Table 2 Sources of heterogeneity in all studies
From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
Potential source of heterogeneity | Studies (n) | I2 | P value |
|---|---|---|---|
Total | 8 | 54% | 0.03 |
Treatment of Control | |||
Placebo (or small dose steroid) | 4 | 75% | 0.009 |
Other immunosuppressants | 4 | 13% | 0.33 |